title: Interleukin-6 attenuates the development of experimental diabetes-related neuropathy.
abstract: Neuropathy is the most severe and the least understood complication of diabetes. We investigated the potential neuroprotective effect of IL-6 therapy in an experimental model of diabetic neuropathy. A single i.v. injection of streptozotocin (STZ, 55 mg/kg) was used to induce experimental diabetes in adult males. IL-6 (1, 10 or 30 microg/kg) was administrated either intraperitoneally on a daily basis or subcutaneously (s.c.) on a daily, on a three times or one time per week basis, starting at day 10 post-STZ. A decrease in sensory nerve conduction velocity (SNCV), indicative of neuropathy, is seen in STZ rats as early as day 10 post-STZ, a time at which blood glycaemia is already maximal. At later time points, this electrophysiological impairment became severe and clinically apparent by affecting tail flick latency. Motor dysfunction defined by a significant increase in compound muscle action potential (CMAP) latency was also recorded. At the completion of the study (day 40 post-STZ), histological examination revealed significant axonopathy and myelin loss, along with an increase in the proportion of fibers with abnormal appearance in sciatic nerves of STZ rats. These changes were not observed in non-diabetic rats and were significantly prevented by IL-6 treatment. The optimal dose appeared to be 10 microg/kg s.c. three injections per week, which showed a better effect in most of the parameters studied than 4-methylcatechol, a NGF-like neuroprotective compound. Once weekly and three times weekly administrations of IL-6 were as effective as daily treatment. Taken together, these results support the potential neuroprotective actions of IL-6. The fact that the half-life of IL-6 is only approximately 5 h while weekly dosing was neuroprotective strongly suggests activation by IL-6 of effector molecule(s) with longer duration of action.
authors.affiliation: Neurofit, Illkirch, France. andriambeloson@neurofit.com
authors.forename: Emile
authors.initials: E
authors.lastname: Andriambeloson
authors.forename: Caroline
authors.initials: C
authors.lastname: Baillet
authors.forename: Pierre-Alain
authors.initials: PA
authors.lastname: Vitte
authors.forename: Gianni
authors.initials: G
authors.lastname: Garotta
authors.forename: Michel
authors.initials: M
authors.lastname: Dreano
authors.forename: Noelle
authors.initials: N
authors.lastname: Callizot
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D002396:Catechols / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D003929:Diabetic Neuropathies / Q000473:pathology / Q000517:prevention & control*; D004576:Electromyography; D015850:Interleukin-6 / Q000627:therapeutic use*; D008297:Male; D018696:Neuroprotective Agents / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D002396:Catechols; D015850:Interleukin-6; D018696:Neuroprotective Agents; C018599:4-methylcatechol